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Introduction
Thrombolytic therapy is increasingly used as a treatment 
for acute ischaemic stroke. Its adoption into clinical 
practice in the UK has been limited: about 1–2% of all 
patients with acute ischaemic stroke presenting to 
hospital currently receive this treatment.1 However, it is 
not universally available, and there is a ‘postcode lottery’ 
element to the chance of receiving treatment.2 Is there 
an ageist element, too? The answer is yes: for a start, 
thrombolytic therapy is not currently licensed for 
patients aged >80 years in the European Union. The 
debate therefore hangs on a series of questions:
a) Is the lack of approval for treatment of the over 80s 
based on sound evidence?
b) Does age >80 years really affect the risks of 
thrombolysis (chiefly of death and of major intracranial 
haemorrhage)?
c) Does age >80 years affect the likelihood of benefit 
(e.g. reopening the blocked cerebral artery, partial or 
complete reversal of the neurological deficit or 
reducing the risk of major cerebral hemisphere 
swelling with increased intracranial pressure)?
d) Even if the evidence is not robust, are people over 80 
being treated ‘off-label’ in the UK and elsewhere?
e) Is there any role for using specialist brain imaging to 
select those older patients most likely to benefit 
from treatment? 
f) In the light of all these questions, is there a case for 
further randomised controlled trials in patients aged 
>80 years?
Over 80s are the world’s fastest growing age group
All over the world, living to the age of 90, 100 or even older 
is no longer exceptional, and the ‘older old’ (people aged 80 
years and over) are the world’s fastest growing age group.3 
By 2050, the number of people aged over 80 will increase 
several fold (with the estimated relative increases being 
greatest in the developing world); to 6 million in the UK, 13 
million in Brazil and 120 million in China.3 Given this large 
– and steadily increasing – number of people aged over 80, 
the question of whether they should be considered for 
thrombolytic therapy if they have a stroke comes into very 
sharp focus. If the current EU approval is adhered to 
strictly, such people are excluded from treatment by 
virtue of their age alone. So what should happen in the 
UK to the 30,000 or so people aged over 80 each year 
who have an acute ischaemic stroke? The question 
almost has a Shakespearean ring: over 80 with a stroke 
– to treat or not to treat…?
Current controversies: thrombolysis for patients 
with acute ischaemic stroke aged over 80
Stroke is the major cause of disability in the community. Most strokes are due to 
blocked arteries in the brain. Evidence is accumulating that clot-busting drugs improve 
outcome after ischaemic stroke. Recombinant tissue plasminogen activator (rt-PA) is 
licensed for the treatment of selected patients within three hours of acute ischaemic 
stroke in many parts of the world, and stroke services are being developed so that 
eligible patients can receive this treatment as soon as possible after the onset of 
stroke symptoms. However, thrombolysis can cause bleeding into the brain, so the 
treatment should only be given when the benefits outweigh the risks. Controversy 
still exists about the risks and benefits in certain groups of patients, and there is 
variation in practice between stroke physicians, reflecting these uncertainties.
The JRCPE editorial team is delighted that two leading experts have agreed to 
debate the pros and cons of thrombolysis in people over the age of 80 years; one 
of the areas where there is still variation in practice. We hope that readers will 
find this debate enlightening, entertaining and informative. 
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Let’s get the evidence from trials!
P Sandercock
What is the evidence for treatment being restricted 
to the under 80s?
The only agent approved for thrombolysis in stroke is 
recombinant tissue plasminogen activator (rt-PA). There 
have been 11 randomised controlled trials of rt-PA for 
acute ischaemic stroke, which have recruited just under 
4,000 patients.4 In the US, the Food and Drug 
Administration approved rt-PA for acute stroke in 1995, 
but did not set an upper age limit for treatment (the US 
approval was based on a single trial of just 624 subjects). 
However, the European Medicines Agency (EMEA) was 
more cautious. The randomised trials that were 
completed at the time of the submission for approval for 
use in Europe included only 42 patients aged over 80. In 
view of the lack of direct evidence on the effects in older 
people, the EMEA approved the treatment only for 
patients aged under 80. Given the predicted shift to the 
population in the future, including many more older 
people, it is worrying that the evaluation of treatments 
for stroke in older people have been so under-
researched.5 Thrombolysis for stroke is no exception!
Does age affect the risk of death with treatment?
The Cochrane systematic review of the randomised 
trials showed that, overall, rt-PA was associated with a 
non-significant 14% increase in the odds of death.4 
A subgroup analysis of the effect of age on treatment-
related death was not possible.4 The meta-analysis of 
individual patient data from all the available randomised 
trials could have examined whether the risk of death 
from treatment was modified by age, but, surprisingly, it 
did not.6 A systematic review of the non-randomised 
cohort studies comparing outcome after rt-PA treatment 
in patients aged under 80, with patients aged over 80, is 
of some interest. It included six cohort studies with 
2,244 patients, of whom 477 were aged over 80 years.7 
Since the studies were non-randomised, it is quite 
possible that the patients aged over 80 were systematically 
different to the patients aged under 80. As one might 
expect, patients aged over 80 had a higher overall 
mortality, and seemed to have a higher chance of dying 
after treatment with rt-PA, although whether this was 
specifically an effect of the drug was unclear.7 
Does age affect the risk of intracranial haemorrhage 
with treatment?
In the cohort studies, the risks of symptomatic intra-
cranial haemorrhage (the most feared complication of 
thrombolytic therapy) were slightly, but not statistically 
significantly, higher in the older patients, although one 
could not exclude a substantially higher risk of bleeding 
in the older age group.7 
Does age affect the chance of benefit from rt-PA?
The meta-analysis of individual patient data from all the 
available randomised trials could have examined whether 
the benefit from treatment was modified by age, but, 
again surprisingly, it did not.6 In the non-randomised 
cohort studies, the proportion who survived free of 
disability was smaller among the older patients compared 
with the patients under 80.7 This is not to say that older 
people do not benefit at all from treatment, but perhaps 
that the scope for benefit is rather smaller than in 
younger people.
Are people over 80 being treated with rt-PA?
In the Hesse region of Germany, despite high treatment 
rates in younger patients, the percentage actually receiving 
treatment falls steeply with age.8 The same was true in a 
very large multicentre audit of hospitals in the US.9 For 
patients aged 80–89 years the odds of treatment with 
tissue plasminogen activator (tPA) were reduced by 60% 
and for patients aged over 90 years the odds of treatment 
were reduced by 80%.9 However, the rt-PA treatment 
included in the review by Engelter is clearly being used in 
the absence of EU approval in at least some patients over 
80, despite the lack of reliable evidence.7 Whatever else, if 
you are a patient with acute ischaemic stroke aged over 
80, your chance of receiving thrombolysis will depend 
very much on which country you are in and which 
hospital you are treated at. This is unacceptable.
Is there a role for specialist brain imaging?
The standard imaging modality for patients with acute 
stroke being considered for thrombolysis is computed 
tomography (CT) scanning. It is quick, universally available, 
virtually all – even very elderly and quite frail patients – 
can be scanned without delay and it is highly cost-
effective.10 More advanced imaging methods, such as 
magnetic resonance imaging (MRI) scanning and perfusion 
or angiography studies, may give much greater information. 
The Cochrane systematic review did not find any evidence 
that the extra time, effort and potential risk of these 
investigations materially altered the response to rt-PA.4 In 
summary, there is no evidence yet that patients over 80 
are a group particularly likely to be better selected by 
more advanced imaging than any other age group.
Is there a case for further randomised controlled trials?
Reviewing the non-randomised studies of thrombolysis 
in the over-80s, the authors concluded that the imbalances 
in baseline variables and lack of randomisation meant 
there was clearly a need for reliable randomised 
evidence on the balance of risk and benefit.7 They 
concluded: ‘For stroke patients aged over 80, it is safe 
and reasonable to include such patients in randomised 
placebo controlled trials.’7 There are two ongoing trials 
of thrombolysis with tPA versus control which are 
including patients aged >80 years. The International 
Stroke Trial (www.ist3.com) has no upper age limit and 
seeks to recruit 3,100 patients with acute ischaemic 
stroke by mid-2011.11 To date, the trial has recruited 
more than 2,000 patients (almost 1,000 of whom are 
aged over 80). The trial will therefore provide unique 
and reliable data on the balance of risk and benefit in this 
particular age group. IST-3 expects to report its results 
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in early 2012. There is an additional Italian trial called 
TESPI which seeks to recruit 600 patients aged over 80 
within three hours of onset of an acute ischaemic stroke, 
and which has recruited 36 patients at the time of writing 
(Danilo Toni, personal communication).
Conclusion
While it may be acceptable to treat the occasional highly 
selected patient aged over 80, routine use of thrombolytic 
therapy in patients over 80 ‘off label’ is to be avoided until 
more reliable randomised trial evidence is available. Of 
course, some patients may not wish to be exposed to the 
risk of treatment and others may have a very clear view 
that they wish to be treated whatever the risks (and 
despite the lack of direct evidence). For the remainder, 
where both the patient and the doctor are uncertain 
about the value of thrombolytic therapy, recruitment into 
one of the ongoing trials is ethical and to be encouraged. 
Current controversies
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A quarter of all admitted stroke patients in developed 
countries are aged over 80 years. This proportion will 
increase over the next 20 years because of three factors: 
changes in population demographics, improved prevention 
of stroke in middle-aged individuals and improved 
survival of patients after first-ever stroke. Stroke in this 
age group is associated with a high mortality and 
substantial disability, with only one fifth having a reasonable 
or good outcome even with the benefits of stroke unit 
care.1 Hence providing treatments that improve the 
likelihood of a good outcome in this age group is a high 
priority in the provision of stroke care. 
Because of arbitrary age limits in place in the European 
Stroke Thrombolysis trials (European Cooperation Acute 
Stroke Studies, ECASS, I–III) only 42 patients over 80 
years were included in the randomised controlled trials 
of recombinant tissue plasminogen activator (rt-PA). 
Hence some argue that this age group should not be 
treated until more randomised data are available from 
further trials. The introduction of an upper age limit in 
the European licence by the regulatory authority the 
European Medicines Agency (EMEA) has also supported 
overly rigid application of this age limit in current stroke 
practice.  An upper age limit is not in place for any other 
licensed drug therapy.
Such a rigid view fails to recognise that age is a continuum 
and that patients over 80 years old are a heterogeneous 
group comprising, at one end fit, active, healthy individuals 
who are biologically similar to many patients under 80 
years of age and at the other end a group of frail, disabled 
individuals with multiple comorbidities. The very elderly 
are more heterogeneous than younger people in respect 
to their health status, comorbidities, existing drug 
treatments and views on treatment. 
Studies of the effect of ageing on response to drug 
therapy across a range of therapy areas provide two 
broad conclusions. Beneficial therapeutic effects of drug 
treatments may be greater or lesser than those seen in 
younger patients but are never absent. The risk of 
serious adverse drug effects usually increases 
incrementally with age. The introduction of new drug 
An alternative view
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therapies is often associated with suggestions that the 
elderly may not benefit from treatment; suggestions 
which are not subsequently confirmed. When blood 
pressure (BP) lowering therapy was first introduced, the 
prevailing opinion was that BP lowering in those aged 
over 65 years was hazardous.2 Even after subsequent 
trials in the elderly demonstrated benefit, a meta-analysis 
in the 1990s of BP lowering in the very elderly suggested 
that although stroke incidence was decreased by the 
same relative risk ratio as in younger patients, mortality 
might be increased.3 No clear biological mechanism was 
proposed for this but a similar non-significant trend to 
increased mortality was seen in the HYpertension in the 
Very Elderly Trial (HYVET) pilot study.4 However, the 
main HYVET study examining the effect of BP lowering 
in over 80 year olds was stopped early because of a 
significant reduction in overall mortality.5
The treatment effect of intravenous thrombolysis with 
rt-PA for acute ischaemic stroke administered within 
three hours of symptom onset is large, with a 14% 
increase in the likelihood of a good outcome, even taking 
into account the 2–3% of patients who experience 
symptomatic deterioration due to intracerebral 
haemorrhage.6  Thus to deny this treatment to all over 
80 year olds, the risk of symptomatic haemorrhage 
leading to death or disability would have to increase 
from 2–3% to at least 10%, or the efficacy in terms of 
clinical response would have to decrease to less than 
20% of that seen in the trials.
The robustness of the effect of thrombolysis in the 0–3 
hour window has been demonstrated through two 
other studies. First, the demonstration of efficacy in the 
3–4.5 hour window in ECASS III,7 and second, the 
confirmation, in the phase IV observational study Safe 
Implementation of Thrombolysis in Stroke (SITS), of the 
same clinical outcomes and symptomatic haemorrhage 
rate as seen in the randomised controlled trials in a large 
cohort of patients in European centres treated with 
intravenous thrombolysis.8 The SITS study also 
demonstrated that the risk of symptomatic haemorrhage 
as defined by a type II parenchymal haemorrhage with 
death or neurological deterioration of four or more 
point increase in the National Institutes of Health Stroke 
Scale (NIHSS) was 2%. 
Many centres have treated patients over 80 years of age 
who otherwise meet the licensing criteria and have 
reported outcomes and symptomatic haemorrhage 
rates. Comparison of outcomes between older and 
younger patients does not provide data on the 
effectiveness of treatment. Older patients have worse 
outcomes in the trials of stroke unit vs usual medical 
care, but the benefits of stroke unit care were similar in 
all age groups. A systematic review of six studies 
comparing outcomes in 477 patients over 80 years 
receiving thrombolysis with outcomes in the same 
centres from patients <80 years found that the very 
elderly on average had more severe strokes.9 As in 
studies of patients not treated with thrombolysis, the 
outcomes with respect to mortality and good outcome 
were less good in the very elderly, although a very good 
outcome was reported in 26% of over 80 year olds. The 
reported symptomatic intracerebral haemorrhage rate 
was not significantly increased (5.7% vs 5.2%). 
In the SITS database approximately 10% of patients are 
>80 years, with a slightly higher figure for UK SITS centres 
(16%).  A preliminary review of outcomes in those over 80 
years shows a mortality rate and outcome similar to that 
reported in the published meta-analysis. The symptomatic 
haemorrhage rate of 2% was not significantly greater than 
the 1.5% seen in <80 year olds.10 
These data indicate that patients over 80 years meeting 
other criteria for treatment with thrombolysis within 
three hours of symptom onset have a similar risk of 
symptomatic haemorrhage as younger patients.  Although 
age is one of the risk factors for symptomatic intracerebral 
haemorrhage, stroke severity and blood pressure being 
the other main predictors, there is probably no age 
threshold at which the benefits of tissue plasminogen 
activator (tPA) are lost by an excessive bleeding risk in 
patients who otherwise meet the licence criteria. Age is 
one among many factors that need to be considered by 
the stroke specialist in decision-making about thrombolysis 
in individual patients. In a previously well, independent 
individual aged over 80 years who has a stroke of 
moderate severity with normal BP, the benefits of 
treatment considerably outweigh the potential risk of 
symptomatic haemorrhage. 
Further randomised controlled trials will provide data 
on the risks and benefits of thrombolysis in patients 
treated in later time windows and in patients where 
clinicians are uncertain of the risks and benefits up to 
4.5 hours. Other studies, such as the Desmoteplase in 
Acute Ischemic Stroke Trial, will determine whether 
advanced imaging can select patients who are more 
likely to benefit from thrombolysis in later time windows. 
However, given that age is only one factor influencing the 
risk and benefit of thrombolysis, it is not logical or 
appropriate to design and conduct acute stroke trials 
only recruiting the over-80-year-old population. Future 
stroke trials should not include upper age limits in their 
inclusion criteria.
Non-randomised data offer an underutilised opportunity 
to determine the safety of thrombolysis in different 
patient groups when randomised controlled trial data are 
absent. One example is the recent demonstration that the 
combination of aspirin and clopidogrel at presentation is 
associated with an increased risk of symptomatic 
intracerebral haemorrhage following intravenous 
thrombolysis.11 Case control studies from well-defined 
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cohorts such as the Virtual International Stroke Trials 
Archive also offer the opportunity to determine the 
effectiveness of thrombolysis in different patient groups.
The stroke physician at the side of the patient’s trolley 
in the emergency room would benefit from the availability 
of bedside decision-making tools that define the likely 
benefits and risks in individual patients. However, for 
most patients including the very old with a potentially 
disabling stroke deficit without contraindications to 
thrombolysis, clinicians can be reassured that the risk–
benefit ratio is highly favourable.
(This article is based on a talk given in a debate at the 
UK Stroke Forum in Glasgow, December 2009.)
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